Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy

Anish B. Parikh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Che‐Kai Tsao(Mount Sinai Hospital), Steven K. Clinton(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Xiaobo Zhong(Icahn School of Medicine at Mount Sinai), Philip Garcia(Icahn School of Medicine at Mount Sinai), Amir Mortazavi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Parissa Alerasool(New York Medical College), Amanda Leiter(Icahn School of Medicine at Mount Sinai), Qian Qin(Icahn School of Medicine at Mount Sinai), Edmund Folefac(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Yuanquan Yang(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Ming Yin(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Vaibhav G. Patel(Icahn School of Medicine at Mount Sinai), William Oh(Women & Infants Hospital of Rhode Island), Bo Wang(Xiamen University), Paul Monk(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), George Mellgard(Memorial Sloan Kettering Cancer Center)
American Journal of Clinical Oncology
January 6, 2021
Cited by 4


Related Papers